{"drugs":["Indium In 111 Pentetreotide","Octreoscan"],"mono":{"0":{"id":"922353-s-0","title":"Generic Names","mono":"Indium In 111 Pentetreotide"},"1":{"id":"922353-s-1","title":"Dosing and Indications","sub":{"0":{"id":"922353-s-1-4","title":"Adult Dosing","mono":"<ul><li>premedicate with a mild laxative such as bisacodyl or lactulose the evening before administration and continue for 48 hours.<\/li><li>encourage liberal fluid intake prior to administration and while patient is receiving laxatives<\/li><li><b>Neuroendocrine tumor; Diagnosis:<\/b> (planar imaging) 111 megabecquerels (3 millicuries) IV; premedicate with mild laxative the night before procedure and continue for 48 hours along with adequate hydration<\/li><li><b>Neuroendocrine tumor; Diagnosis:<\/b> (SPECT imaging) 222 megabecquerels (6 millicuries) IV; premedicate with mild laxative the night before procedure and continue for 48 hours along with adequate hydration<\/li><\/ul>"},"3":{"id":"922353-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Neuroendocrine tumor; Diagnosis<br\/><b>Non-FDA Labeled Indications<\/b><br\/>Graves' disease<br\/>"}}},"3":{"id":"922353-s-3","title":"Contraindications\/Warnings","sub":[{"id":"922353-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"922353-s-3-10","title":"Precautions","mono":"<ul><li>concomitant administration in total parenteral nutrition admixture or injection into TPN line not recommended<\/li><li>concomitant use with octreotide acetate may result in reduced sensitivity to indium In-111 pentetreotide; consider temporarily suspending octreotide therapy and monitor for withdrawal symptoms<\/li><li>insulinomas; severe hypoglycemia may occur; use of IV line and administration of IV glucose before and during administration recommended<\/li><li>radiation dose to thyroid, bladder, kidneys, and target organs, increased level, may occur; increase fluid intake before and 1 day after administration<\/li><li>renal insufficiency<\/li><li>radiopharmaceutical; handle with care and use safety measures to reduce radiation exposure to personnel and patient<\/li><\/ul>"},{"id":"922353-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"922353-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"922353-s-5","title":"Adverse Effects","mono":"<b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Bradyarrhythmia<\/li><li><b>Hematologic:<\/b>Decreased hematocrit level, Decreased hemoglobin<\/li><li><b>Hepatic:<\/b>Liver enzymes abnormal (less than 1%)<\/li><\/ul>"},"6":{"id":"922353-s-6","title":"Drug Name Info","sub":{"0":{"id":"922353-s-6-17","title":"US Trade Names","mono":"Octreoscan<br\/>"},"2":{"id":"922353-s-6-19","title":"Class","mono":"Diagnostic Agent, Radiopharmaceutical Imaging<br\/>"},"3":{"id":"922353-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"922353-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"922353-s-7","title":"Mechanism Of Action","mono":"Systemic: Pentetreotide, a diethylenetriaminopentaacetic (DTPA) conjugate of octreotide (an analog of somatostatin), binds to somatostatin receptors on cell surfaces throughout the body. Tumors containing a high density of somatostatin receptors concentrate indium In 111-labeled pentetreotide. After clearance of blood activity, visualization of somatostatin receptor-positive tissue is achieved with scintigraphic imaging techniques.<br\/>"},"8":{"id":"922353-s-8","title":"Pharmacokinetics","sub":{"2":{"id":"922353-s-8-25","title":"Metabolism","mono":"<ul><li>Total body: minimal<\/li><li>Indium-111-diethylenetriamine pentaacetic acid (DTPA): unknown.<\/li><\/ul>"},"3":{"id":"922353-s-8-26","title":"Excretion","mono":"<ul><li>Bile: less than 2%<\/li><li>Renal: approximately 100%<\/li><\/ul>"},"4":{"id":"922353-s-8-27","title":"Elimination Half Life","mono":"6 hours <br\/>"}}},"9":{"id":"922353-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>use proper procedures for handling and disposal of radiopharmaceuticals<\/li><li>use drug within 6 hours of preparation<\/li><li>wear waterproof gloves during handling procedure and perform all operations aseptically<\/li><li>place vial in lead dispensing shield (minimum wall thickness, 0.25 inch) with lid<\/li><li>remove contents of vial and with needle provided and shielded syringe and inject into reaction vial; gently swirl contents until pellet is dissolved and then incubate at or below 25 degrees C (77 degrees F) for a minimum of 30 minutes<\/li><li>preparation may be diluted to a maximum volume of 3 mL with 0.9% Sodium Chloride immediately prior to injection<\/li><\/ul>"},"10":{"id":"922353-s-10","title":"Monitoring","mono":"<ul><li>quality scintigraphic images of somatostatin-containing tumor lesions are indicative of efficacy<\/li><li>no specific toxic monitoring has been determined<\/li><\/ul>"},"11":{"id":"922353-s-11","title":"How Supplied","mono":"<b>Octreoscan<\/b><br\/>Injection Kit: 3 MCI\/ML<br\/>"},"13":{"id":"922353-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause headache, dizziness, fever, arthralgia, nausea, sweating, or weakness.<\/li><li>Advise patient to stay hydrated and void as often as possible prior to and for at least 1 day after administration.<\/li><\/ul>"}}}